Clinical Trials Directory

A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults

This randomized phase III trial studies combination chemotherapy with blinatumomab to see how well it works compared to induction chemotherapy alone in treating patients with newly diagnosed breakpoint cluster region (BCR)-c-abl oncogene 1, non-receptor tyrosine kinase (ABL)-negative B lineage acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as blinatumomab, may block cancer growth in different ways by targeting certain cells. It is not yet known whether combination chemotherapy is more effective with or without blinatumomab in treating newly diagnosed acute lymphoblastic leukemia.

Stanford is now accepting new patients for this trial.



  • biological : blinatumomab
  • drug : daunorubicin hydrochloride
  • drug : vincristine sulfate
  • drug : dexamethasone
  • drug : methotrexate
  • drug : pegaspargase
  • drug : mercaptopurine
  • drug : cytarabine
  • drug : cyclophosphamide
  • drug : prednisone
  • drug : etoposide
  • other : laboratory biomarker analysis
  • procedure : allogeneic hematopoietic stem cell transplantation

Phase: Phase 3


Ages Eligible For Study:

30 Years - 70 Years

External Links

Explore related trials

Contact information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Kellie Baumann

Footer Links: